Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Quadruples Q3 Revenues, But Loss Widens as it Prepares Bacterial Analysis System

NEW YORK, June 16 (GenomeWeb News) - Accelr8 Technology yesterday reported increased revenues along with a widened loss for its third quarter of fiscal 2005, which ended April 30.

 

The Denver-based company had $120,000 in revenues for the quarter, more than four times the $26,000 it posted during the same period a year ago. This increase was attributed to sales of two types of microarray slides, Slide H and Slide HS, which Accelr8 licenses and manufactures for Schott Nexterion.

 

Research and development costs nearly tripled for the quarter, however, to $383,000, from $128,000 during the same quarter last year. the company attributed the increase to the development of its BACcelr8r rapid bacterial analysis system.

 

As a result, Accelr8's net loss for the quarter soared to $563,000, or $.06 per share, from $335,000, or $.03 per share, during the year-ago period.

 

As of April 30, Accelr8 had $5.9 million in cash and cash equivalents.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.